| Literature DB >> 23816479 |
Eric Kerns, Shweta Patel, David M Cohen.
Abstract
Hypertonic NaCl is first-line therapy for acute, severe and symptomatic hyponatremia; however, its use is often restricted to the intensive care unit (ICU). A 35-year-old female inpatient with an optic chiasm glioma and ventriculoperitoneal shunt for hydrocephalus developed acute hyponatremia (sodium 122 mEq/l) perhaps coinciding with haloperidol treatment. The sum of her urinary sodium and potassium concentrations was markedly hypertonic vis-à-vis plasma; it was inferred that serum sodium concentration would continue to fall even in the complete absence of fluid intake. Intravenous (i.v.) 3% NaCl was recommended; however, a city-wide public health emergency precluded her transfer to the ICU. She was treated with hourly oral NaCl tablets in a dose calculated to deliver the equivalent of 0.5 ml/kg/h of 3% NaCl with an objective of increasing the serum sodium concentration by 6 mEq/l. She experienced a graded and predictable increase in serum sodium concentration. A slight overshoot to 129 mEq/l was rapidly corrected with 0.25 l of D5W, and she stabilized at 127 mEq/l. We conclude that hourly oral NaCl, in conjunction with careful monitoring of the serum sodium concentration, may provide an attractive alternative to i.v. 3% NaCl for selected patients with severe hyponatremia.Entities:
Mesh:
Substances:
Year: 2014 PMID: 23816479 PMCID: PMC4750111 DOI: 10.5414/CN108014
Source DB: PubMed Journal: Clin Nephrol ISSN: 0301-0430 Impact factor: 0.975
Laboratory data obtained at admission and at time of nephrology consultation.
| Determination | Value: admission | Value: time of consultation |
|---|---|---|
| Serum Na+ concentration | 132 mEq/L | 122 mEq/L |
| Serum K+ concentration | 4.4 mEq/L | 4.3 mEq/L |
| Serum creatinine | 1.2 mg/dL | 0.7 mg/dL |
| Serum osmolality | 251 mOsmol/kg H2O | |
| Urine osmolality | 410 mOsmol/kg H2O | |
| Urine Na+ concentration | 138 mEq/L | |
| Urine K+ concentration | 21 mEq/L |
Figure 1.Data reflecting the clinical course. A: Trajectory of serum sodium concentration (mEq/L) as a function of time (in hours). Events (marked on timeline as arrowhead) are as follows: 1 – intravenous administration of 1 l normal saline; 2 – large-volume paracentesis of 3.2 l ascitic fluid; 3 – administration of 0.5 l of normal saline; 4 – imposition of 1.5 l/d fluid restriction; and 5 – treatment with oral NaCl tablets. The interval during which haloperidol was administered (total of 7 mg divided in 14 oral and parenteral doses) is marked with a horizontal gray bar. The shaded area (marked “C”) is expanded in Panel C. The final four [Na+] determinations were obtained as an outpatient. B: Recorded fluid intake and urinary output (in l) in 24-hour intervals corresponding approximately to the x-axis timeline in Panel A; data for the 6th day are partial (incomplete), and data were not recorded beyond Day 6. The 24-hour intervals in B deviate by 4 hours from the interval in Panel A (time: 21:00 – 21:00 in A; 01:00 – 01:00 in B). Although not evident from the daily totals in B, much of the copious urine output on the 3rd and 4th hospital days (i.e., between hours 48 – 96) spontaneously occurred during the 8-hour overnight interval centered on Hour 72 in Panel A and totaled 2.6 l. C: Detailed trajectory of serum sodium concentration (representing shaded interval in Panel A) in response to hourly administration of NaCl (1 g tablets; filled arrowhead for each dose). Although prescribed hourly, the timing of administration was variable; depicted data reflect time of actual NaCl administration. At a serum [Na+] of 129 mEq/L, D5W (0.25 l) was administered intravenously (open arrowhead) with a resultant decrease in serum [Na+] to 127 mEq/L.